Explore more publications!
Idaho Healthcare Hub
Submit Press Release

Idaho Healthcare Hub: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Idaho Healthcare Hub.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on October 23, 2025

Progyny, Inc. Announces Details for Its Third Quarter 2025 Results Report
October 23, 2025

Progyny, Inc. Announces Details for Its Third Quarter 2025 Results Report

Indeterminate GlobeNewswire
Europe Approves New Alzheimer’s Treatment -- Why is the U.S. Still Waiting?
October 23, 2025

Europe Approves New Alzheimer’s Treatment -- Why is the U.S. Still Waiting?

Indeterminate GlobeNewswire
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
October 23, 2025

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Indeterminate GlobeNewswire
Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025.
October 23, 2025

Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025.

Indeterminate GlobeNewswire
Guerbet : Chiffre d’affaires au 30 septembre 2025. Retour de la croissance au 3ème trimestre 2025. Confirmation de l’ensemble des objectifs financiers 2025.
October 23, 2025

Guerbet : Chiffre d’affaires au 30 septembre 2025. Retour de la croissance au 3ème trimestre 2025. Confirmation de l’ensemble des objectifs financiers 2025.

Indeterminate GlobeNewswire
Rentschler Biopharma Inc. named Manufacturer of the Year for Central Massachusetts
October 23, 2025

Rentschler Biopharma Inc. named Manufacturer of the Year for Central Massachusetts

Indeterminate GlobeNewswire
Roxanna Gapstur, Ph.D., R.N., WellSpan president and CEO, named a Distinguished Daughter of PA
October 23, 2025

Roxanna Gapstur, Ph.D., R.N., WellSpan president and CEO, named a Distinguished Daughter of PA

Indeterminate GlobeNewswire
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
October 23, 2025

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

Indeterminate GlobeNewswire
BeautyHealth to Report Third Quarter 2025 Financial Results on November 6, 2025
October 23, 2025

BeautyHealth to Report Third Quarter 2025 Financial Results on November 6, 2025

Indeterminate GlobeNewswire
CHESS Health and Diamond Mind Partner to Deliver Groundbreaking Veteran-Focused Support
October 23, 2025

CHESS Health and Diamond Mind Partner to Deliver Groundbreaking Veteran-Focused Support

Indeterminate GlobeNewswire
Visory Health Partners with Albertsons Companies to Expand Access to Affordable Prescriptions Nationwide
October 23, 2025

Visory Health Partners with Albertsons Companies to Expand Access to Affordable Prescriptions Nationwide

Indeterminate GlobeNewswire
Synfini Selected for SLAS 2026 Innovation AveNEW Showcase
October 23, 2025

Synfini Selected for SLAS 2026 Innovation AveNEW Showcase

Indeterminate GlobeNewswire
Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform
October 23, 2025

Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform

Indeterminate GlobeNewswire
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
October 23, 2025

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

Indeterminate GlobeNewswire
Global Drug Delivery Systems (DDS) Market Transforms Amid New Pharma Demands
October 23, 2025

Global Drug Delivery Systems (DDS) Market Transforms Amid New Pharma Demands

Indeterminate GlobeNewswire
SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
October 23, 2025

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Indeterminate GlobeNewswire
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
October 23, 2025

Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women

Indeterminate GlobeNewswire
Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
October 23, 2025

Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program

Indeterminate GlobeNewswire
MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
October 23, 2025

MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

Indeterminate GlobeNewswire
B.C.’s ‘Cost Recovery’ Act on Vaping, Could Become a Costly Mistake
October 23, 2025

B.C.’s ‘Cost Recovery’ Act on Vaping, Could Become a Costly Mistake

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions